184. Sarah Meyer Thompson, CEO of Mg Biologics on Performing Reasearch Trials and Disrupting The Equine Industry in The Best Ways Possible

How'd She Do That?

Today's guest is the CEO of Mg Biologics, Sarah Meyer Thompson. Sarah's father, Mark Meyer, started Mg Biologics in 1999. It was here at Mg where she learned about antibodies, performed research trials, and launched new products for the equine neonatal industry.

Mark remains involved with Mg as Chairman of the Board, however, he has passed the CEO reigns (horse pun intended) to Sarah. She is honored to be leading Mg Biologics as they press forward.

Their products are focused on how to benefit your animal’s health, from neonatal to critical care needs. This includes plasma, IgG, antibody products, and antivenom for equine and canine. They believe (and research shows) that antibodies (and antivenom) are beneficial in reducing the duration and severity of a disease or in arresting the disease entirely. More importantly, Mg proudly continues in the spirit that Mark founded nearly 20 years ago: “Of the principles that we hold most dear, we consider customer service to be especially satisfying. Even to say it more clearly; sometimes when things don’t go right (because sometimes they don’t) we make an extra effort to see that the customer is taken care of. We are fanatical, intense, wound-tight, and high-strung on this point.”

This month's sponsor of HSDT is Anna Bradshaw Content Co. Anna Bradshaw Content Co. helps brands grow online engagement loyalty, and conversations through smart content marketing. Go to annakbradshaw.com to learn more!

--- Support this podcast: https://podcasters.spotify.com/pod/show/howdshedothat/support